Additionally, those with liver dysfunction, concomitant use of a strong CYP3A4 inhibitor, or of Asian race may require a lower initiation dosage because of observed increases in osilodrostat exposure and bioavailability in these populations [22, 23, 44]. Here, CYP3A4 is linked to Decreased liver function.